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CASE REPORT
Conventional radiation therapy (RT) is a widely recognized treatment for hepatocellular carcinoma (HCC).
However, conventional RT plays only a limited role in HCC treatment because of its low efficacy and the low toler-
ance of the liver for this modality. Stereotactic body radiation therapy (SBRT) was recently developed and repre-
sents the most advanced radiation therapy technique currently available. It can deliver a high dose in a short time
to well-defined hepatic tumors, with rapid dose fall-off gradients. We believe that SBRT with transarterial chemolip-
iodolization (TACL) may prove promising as a combined treatment modality for HCC due to its precision and rela-
tive safety. Here we present a case of successful treatment of advanced HCC with obstructive jaundice using this
combined modality. (Korean J Intern Med 2011;26:94-98)
Keywords: Hepatocellular carcinoma; Stereotactic body radiation therapy; Transarterial chemolipiodolization;
Obstructive jaundice
Received: July 31, 2007
Revised  : September 3, 2007
Accepted: June 10, 2008
Correspondence to Si-Hyun Bae, M.D.
Department of Internal Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, 505 Banpo-dong, Seocho-gu, Seoul 137-040,
Korea
Tel: 82-2-2258-6020, Fax: 82-2-3481-4025, E-mail: baesh@catholic.ac.kr
INTRODUCTION 
Conventional radiation therapy (RT) is a widely recog-
nized treatment for hepatocellular carcinoma (HCC).
However, conventional RT currently plays only a limited
role in HCC treatment due to its low efficacy and the low
tolerance of the liver for its effects. The total dose of irradi-
ation has been shown to be the most significant factor
associated with response [1]. Cell survival with lengthy
treatment time was increased, presumably as a conse-
quence of cellular repair mechanisms. To improve local
tumor control and overall survival, dose escalation during
short treatments has become an important issue. It is not
possible with conventional RT to deliver a high radiation
dose to a treatment volume in a short time without also
irradiating some normal hepatic tissue with a high dose.
Stereotactic body radiation therapy (SBRT) is the only
modality that can deliver a high dose in a short time to
well-defined hepatic tumors with a rapid dose fall-off gra-
dient. SBRT was initially used only for benign and malig-
nant intracranial lesions with the advent of advanced
imaging techniques and robotic image-guided radiation
technologies [2,3].
Recently, local, not whole liver, RT has been attempted
by several investigators, and this work has demonstrated
that high doses of radiation can be safely delivered to a
portion of the liver [4]. These results suggest a benefit of
the combination of radiation and chemotherapy for
advanced HCC with portal vein tumor thrombosis (PVTT). 
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chemolipiodolization (TACL) treatment for advanced
HCC developing extrahepatic biliary obstruction (EHBO),
which showed a partial response and safety. 
CASE REPORT
A 63-year-old man was admitted to our hospital com-
plaining of epigastric discomfort and jaundice. He was
diagnosed as a hepatitis B virus (HBV) carrier, a status he
had held for 20 years without receiving treatment. He had
complained of epigastric discomfort with abdominal
bloating and jaundice with pruritus a few months previ-
ously associated with a 25-kg body weight loss over the
previous three months. He had no history of herb medica-
tion or travel. 
His initial blood pressure was 120/80 mmHg, pulse rate
78/min, respiratory rate 20/min, and body temperature
was 36.4°C. The physical examination showed icteric scle-
rae and no palpable mass, abdominal distention, and
shifting dullness. Laboratory findings showed white blood
cell 4,190/µL, hemoglobin 10.2 g/dL, hematocrit 28.3%,
platelet 145,000/µL, prothrombin time (PT) 115% of nor-
mal PT, INR 0.93, aPTT (control/test) 29.5/31.8 sec, fast-
ing blood glucose 96 mg/dL, urea nitrogen 20.4 mg/dL,
creatinine 1.41 mg/dL, total protein 6.59 g/dL, albumin
3.02 g/dL, aspartate aminotransferase (AST) 57 U/L, ala-
nine aminotransferase (ALT) 39 U/L, alkaline phos-
phatase 687 IU/L, gamma-glutamyl transpeptidase
(GGTP) 39 U/L, total bilirubin 56.66 mg/dL, direct biliru-
bin 34.84 mg/dL, alpha-fetoprotein (AFP) 613 ng/dL, and
PIVKA II > 2,000 mAU/mL. The serum hepatitis B sur-
face antigen was positive, and hepatitis C antibody was
negative. Hepatitis B e antigen was negative, e antibody
was positive, and HBV DNA titer was 2.0 ×10
3copies/mL.
The abdominal CT scan revealed a 5.6 × 5-cm-sized
arterial enhancing, delayed-washout mass with a central
necrotic portion in the caudate lobe of liver (S1), left intra-
hepatic bile duct dilatation, right portal vein invasion, and
underlying liver cirrhosis with splenomegaly and ascites.
The diagnosis was likely HCC and less likely cholangiocar-
cinoma (Fig. 1).
First, percutaneous transhepatic cholangiographic
drainage was performed to lower the elevated bilirubin
and to diminish the pruritus. The fistulography revealed
hilar and proximal common hepatic duct obstruction with
left intrahepatic duct dilatation (Fig. 2); this suggested
right lobar hepatic malignancy with hilar invasion. The
level of total bilirubin was decreased from 57.66 mg/dL to
38.51 mg/dL after the procedure of external bile drainage.
However, the bilirubin level was not decreased any more
even though maintaining the draining catheter.
Four gold markers were inserted around the region of
the target under sono guidance to act as radiographic
landmarks. The CyberKnife (Accuracy Inc., Sunnyvale,
Figure 1. Abdominal computed tomography scan showing a
5.6 × 5-cm-sized arterial and portal enhancing, delayed-
washout mass with a central necrotic portion in segment 1. It is
likely that intrahepatic bile duct dilatation and right portal vein
and hilar invasion are also present. Underlying liver cirrhosis
with splenomegaly and ascites is also present. 
Figure 2. Percutaneous transhepatic biliary drainage showing
hilar and proximal common hepatic duct obstruction with left
intrahepatic duct dilatation. There is non-opacification of the
right intrahepatic duct, suggesting right lobar hepatic malig-
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CA, USA) was targeted to the unresectable primary HCC.
Circumscribed tumors were irradiated using a hypofrac-
tionated treatment. The total doses administered were 37
Gy with a prescription isodose at 80% in three fractions
over three consecutive days. At 3 months after CyberKnife
treatment, the size of the mass had decreased from 5.6 × 5
cm to 4.8 × 3.2 cm as determined by CT scan (Fig. 3), and
total bilirubin and AFP levels had decreased from 33.60 to
9 mg/dL and 613 to 300 ng/dL, respectively. After 4
months, TACL was performed three times per month to
reduce the HCC mass, and angiography showed an infil-
trating HCC at the caudate lobe without definite hypervas-
cular staining. Following consecutive post-CyberKnife
TACL treatments, symptoms (jaundice, pruritus, and
abdominal discomfort) were much improved. Finally,
total bilirubin and AFP levels decreased dramatically from
33.60 to 1.83 mg/dL and from 613 to 0.64 ng/dL, respec-
tively (Fig. 4). In addition, angiography showed no tumor
staining at the caudate lobe in the 3rd TACL (Fig. 5).
Thereafter, liver transplantation was performed success-
fully two months later. The patient was followed-up regu-
larly on an outpatient basis.
DISCUSSION
HCC is the fifth most common cancer and the third
most frequent cause of death from cancer worldwide.
However, in Korea, it is the third most frequent cause of
death and is more prevalent among men in their fourth to
fifth decades of life [5].
Jaundice occurs in 19 to 40% of patients with HCC at
the time of diagnosis and usually occurs in the later stages
of the disease. HCC may involve the biliary tract in several
different ways: tumor thrombi, hemobilia, tumor com-
pression, and diffuse tumor infiltration. Rarely, jaundice
may be occurred due to external compression of the major
bile ducts by direct tumor encasement or by metastatic
lymphadenopathy at the porta hepatis. The clinical fea-
tures of this type of HCC include high serum AFP level, a
history of cholangitis with dilation of the intrahepatic bile
duct, aggravating jaundice, and rapidly development of
liver dysfunction. The total serum bilirubin level can
Figure 3. Abdominal computed tomography scan showing a
slight decrease in the dimensions of the hypervascular mass
involving the caudate lobe (4.8 × 3.2 cm).
Figure 4. Changes in total bilirubin and AFP levels during the
treatment. PTBD, percutaneous transhepatic cholangiographic
drainage; TB, total bilirubin; AFP, alpha-fetoprotein; TACL,
transarterial chemolipiodolization. 
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Figure 5. Angiography showing no definite hypervascular
staining at the caudate lobe.Park CK, et al. CyberKnife with TACL for HCC developing biliary obstruction   97
increase rapidly and is correlated with alkaline phos-
phatase and gamma-GTP levels.
Based on the underlying pathophysiology, the develop-
ment of jaundice in HCC can be classified into two types:
hepatocellular and cholestatic. Hepatocellular HCC is
attributed to an underlying liver cirrhosis and extensive
hepatic parenchymal infiltration by the tumor, which
leads to hepatic parenchymal insufficiency. Over 90% of
HCC cases with jaundice belong to this type. Some cases
may have a reversible cause, such as reactivation of an
underlying viral hepatitis or other toxic hepatitis, and
should be excluded [6]. In cholestatic HCC, jaundice is
caused by obstruction of the bile ducts by the tumor.
Mallory et al. [7] described the first case of HCC invading
the gall bladder and obstructing the extrahepatic bile
ducts. The incidence of cholestatic-type HCC varies from
0.5 to 13%. Increasing recognition of cholestatic-type HCC
renders classification according to therapeutic implica-
tions necessary. Lau et al. [6] classified cholestatic-type
HCC into extrahepatic and the intrahepatic subtypes. This
has significant therapeutic and prognostic value because
those patients with EHBO secondary to HCC have a high-
er curative resection rate, which results in a significantly
improved survival rate compared with those with intra-
hepatic biliary obstruction. Evidence from previous stud-
ies suggested that the management and prognosis of
patients with HCC associated with jaundice depends on
the underlying cause of the jaundice [8].
The management of cholestatic-type HCC includes two
considerations. The first is to stabilize the jaundice by
insertion of a draining catheter into the obstructed biliary
tree, and the second is to assess the resectability of the
tumor using appropriate investigations. Depending on the
degree of biliary obstruction and the general condition of
the patient, these two aspects of management can be car-
ried out in one or two phases [8].
For patients with unresectable cholestatic-type HCC,
palliative biliary drainage should be carried out. This can
relieve jaundice and improve the patient's quality of life.
For patients whose liver function improves after biliary
drainage, other palliative treatments, such as tran-
scatheter arterial chemoembolization, internal radiothera-
py, or systemic chemotherapy, should be considered [9].
Currently, radiation therapy is the most common treat-
ment for HCC, and it has been reported to have beneficial
effects, not only on the main tumor but also on PVTT
associated with HCC. However, its role is currently limited
because of the very low radiation tolerance of normal
hepatic tissue [10]. The combination of three-dimensional
conformal radiation therapy with TACL for HCC in cir-
rhotic patients was introduced as an alternative local
modality, and the response rate was reported to be about
50% in HCC with PVTT [11,12]. Some authors have
reported that the liver-tolerable dose depends on the vol-
ume of liver irradiated, and a small volume of liver tissue
can tolerate a higher dose of radiotherapy [13]. It is not
possible with conventional radiation therapy to deliver a
high radiation dose to a treatment volume without expos-
ing some normal hepatic tissue to high-dose irradiation.
However, SBRT with the CyberKnife can deliver a high
dose to well-defined hepatic tumors with an associated
rapid dose fall-off outside the tumor volume and preserva-
tion of normal hepatic tissue. Blomgren et al. [14] were the
first to report use of stereotactic radiation in the treatment
of liver malignancies. They suggested a fractionated radia-
tion schedule and reported (after exclusion of the first five
patients) only one failure out of 41 liver malignancies.
Herfarth et al. [2] reported that 54 (98%) of 55 tumors
were locally controlled after six weeks (the initial follow-
up) based on computer tomographic findings after a
stereotactic single-dose radiation treatment of 60 liver
tumors in 37 subjects. Recently, Kwon et al. [3] demon-
strated that SBRT for small HCC less than 32 cc in tumor
volume that are ineligible for local treatments showed 25
(59.6%) of 42 patients with complete response and 11
(26.2%) patients with partial response for in-field lesion.
Therefore, SBRT may be preferable to either conventional
or conformal radiotherapy. Furthermore, in cases of
advanced or huge HCC developing obstructive jaundice,
combined local SBRT with TACL therapy may prevent the
tumor from spreading and lead to relief of obstructive
jaundice.
The prognosis of patients with cholestatic-type HCC is
generally dismal, but is usually better than that of HCC
patients who have jaundice caused by hepatic insufficien-
cy. The prognosis of this type is closely related to the stage
of disease and the location and extent of tumor thrombi in
the bile duct. In a study of 49 HCC patients with obstruc-
tive jaundice, Lau et al. [9] reported that nine patients
received curative resection, 35 had biliary stents, and five
required only supportive treatment. The overall survival
rate of these patients was similar to that of HCC patients
without jaundice. They concluded that good palliation and
occasional cure were possible with proper treatment.98 The Korean Journal of Internal Medicine Vol. 26, No. 1, March 2011
In conclusion, even though the available clinical data
are insufficient to explain the outcome of this case, we
believe that SBRT with TACL may represent an appropri-
ate treatment modality for advanced HCC with obstruc-
tive jaundice due to its precision and relative safety.
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